EyePoint (EYPT) Other Working Capital Changes (2018 - 2025)
EyePoint (EYPT) posted Other Working Capital Changes of -$6000.0 for Q1 2026, up 14.29% sequentially from -$7000.0 in Q4 2025, and up 99.97% YoY from -$3000.4 in Q1 2025.
Analysis
EyePoint (EYPT) Other Working Capital Changes (2018 - 2025) Analysis & Trends
EyePoint has reported Other Working Capital Changes for 9 years, with the latest figure at -$6000.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 99.97% year-over-year to -$6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.5 million (up 151.76% YoY) and the FY2025 annual result came in at -$33000.0, up 99.89% from the prior year.
- Other Working Capital Changes improved to -$6000.0 in Q1 2026 per EYPT's latest filing, from -$7000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $495000.0 in Q4 2017 and troughed at -$1.1 million in Q1 2014.
- A 5-year average of -$93222.2 and a median of -$9500.0 in 2015 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 36260.61% in 2023, down 6191.22% in 2023.
- Over 5 years, Other Working Capital Changes stood at -$205000.0 in 2022, then sank by 6191.22% to -$12.9 million in 2023, then plunged by 137.62% to -$30.6 million in 2024, then jumped by 99.98% to -$7000.0 in 2025, then increased by 14.29% to -$6000.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$6000.0, -$7000.0, and -$8000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -5.12 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Mar 31, 2025 | -23.52 Mn |
| Mar 31, 2025 | -23.52 Mn |
| Dec 31, 2024 | -8.59 Mn |
| Dec 31, 2024 | -8.59 Mn |
| Sep 30, 2024 | -7.78 Mn |
| Sep 30, 2024 | -7.78 Mn |
| Jun 30, 2024 | -5.47 Mn |
| Jun 30, 2024 | -5.47 Mn |
| Mar 31, 2024 | -8.80 Mn |
| Mar 31, 2024 | -8.80 Mn |
| Dec 31, 2023 | -12.90 Mn |
| Dec 31, 2023 | -12.90 Mn |
| Sep 30, 2023 | -13.92 Mn |
| Sep 30, 2023 | -13.92 Mn |
| Jun 30, 2023 | 71.60 Mn |
| Jun 30, 2023 | 71.60 Mn |
| Mar 31, 2023 | -255,000.00 |
| Mar 31, 2023 | -255,000.00 |